Detalhe da pesquisa
1.
Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination.
J Infect Dis
; 2024 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38682569
2.
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
Lancet
; 399(10323): 461-472, 2022 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35065705
3.
Safety and Immunogenicity of a New Inactivated Polio Vaccine Made From Sabin Strains: A Randomized, Double-Blind, Active-Controlled, Phase 2/3 Seamless Study.
J Infect Dis
; 226(2): 308-318, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33351072
4.
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination.
J Infect Dis
; 225(9): 1521-1532, 2022 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33319249
5.
Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003).
Clin Infect Dis
; 75(1): 107-117, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34606595
6.
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents.
N Engl J Med
; 381(21): 2009-2019, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31693803
7.
Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
Lancet
; 395(10234): 1423-1433, 2020 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32197105
8.
A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years.
BMC Infect Dis
; 20(1): 426, 2020 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32552685
9.
Prevalence and Incidence of Respiratory Syncytial Virus and Other Respiratory Viral Infections in Children Aged 6 Months to 10 Years With Influenza-like Illness Enrolled in a Randomized Trial.
Clin Infect Dis
; 60(11): e80-9, 2015 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25673560
10.
Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
BMC Infect Dis
; 15: 409, 2015 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26437712
11.
Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial.
J Infect Dis
; 210(4): 545-57, 2014 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24652494
12.
Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Glob Health
; 12(2): e257-e270, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38245116
13.
Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.
BMC Infect Dis
; 13: 116, 2013 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-23510357
14.
Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue.
Am J Trop Med Hyg
; 108(4): 722-726, 2023 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36878213
15.
Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study.
Vaccine
; 41(11): 1875-1884, 2023 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36781334
16.
Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents.
Hum Vaccin Immunother
; 19(1): 2206359, 2023 12 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37226504
17.
A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age.
Lancet Reg Health West Pac
; 24: 100484, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35664443
18.
Solithromycin in Children and Adolescents With Community-acquired Bacterial Pneumonia.
Pediatr Infect Dis J
; 41(7): 556-562, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35675525
19.
Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35â¯months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.
Vaccine
; 37(13): 1876-1884, 2019 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30558818
20.
Antibody Persistence up to 3 Years After Primary Immunization With Inactivated Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a Booster Dose.
Pediatr Infect Dis J
; 37(9): e233-e240, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29912844